Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Well market not happy !
View:
Post by Thor6570 on Jul 30, 2020 9:41am

Well market not happy !

If you believe shares are on sale !
Comment by 2for1split on Jul 30, 2020 9:56am
It's not like we were priced for perfection. This is just a blip, no reasoon to be punished for a 60% CR. I dont think you will find any other company with a 35 million MC demonstrating 60% CR in a phase 2 trial.
Comment by StevenBirch on Jul 30, 2020 10:44am
I agree, seems like after overblown response like there was to P4 in Phase I. Also maybe Covid did us a favour, better to fine tune screening and under dosing glitches after 12 patients being treated  rather than 100. Just like we saw great improvement for P5 and P6 the next slew of results will tell the real tale.
Comment by goldn1 on Jul 30, 2020 10:54am
shouldnt the fine tuning been done before tlt stuck this drug in people's bladders? I thought Lildge an Betz already resolved the bladder volume issue... Hard to make lemonade out of this release, looks like they don't know how to treat ppl...
Comment by fasttrack5 on Jul 30, 2020 11:07am
Comment by Quattro74 on Jul 30, 2020 11:38am
The beatings will continue until morale improves.  Seriously though. This is actually kinda bad. only 25% CR as Pando suggests. So yes we are seeing a sell off. I hope that Doctors Lilge et al will figure out the fine tuning so the numbers will improve dramatically from here. Also, 8 are eligible for a second treatment, so we could still see as much as 67% 1yr CR from these first 12. That ...more  
Comment by xodcode on Jul 30, 2020 12:50pm
Had to purchase some more shares just now. TLT a bargain at this price!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250